The Psychedelic Therapies Executive Order
I Glenn Cohen, Holly Fernandez Lynch, Al Mcguire
JAMA July 1, 2026 DOI: 10.1001/jama.2026.11892 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Viewpoint Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Executive order Order exchange Medline Ethical issues Drug approval Psychotherapist Engineering ethics |
| Key points | The executive order backs psychedelic drug development and approval, yet ethical and evidence-based issues complicate their clinical integration. |
Abstract
This Viewpoint discusses the executive order supporting the development and approval of psychedelic drugs and outlines issues surrounding their ethical and evidence-based integration into clinical care.